PPARGC1A and cyst: Consistent with our earlier observations, the primary cellular consequence of anti-miR-17 treatment was improved expression of metabolism-related gene networks, including the upregulation of direct miR-17 target Pparα and Ppargc1a. Thus, one of the direct mechanisms by which anti-miR-17 mediates its cyst-reducing effects may be through improvement in cyst metabolism.